Last reviewed · How we verify

Reckitt Benckiser Inc. — Portfolio Competitive Intelligence Brief

Reckitt Benckiser Inc. pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Mucinex® SE Mucinex® SE marketed Expectorant Respiratory/Cold & Cough

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. American Health Research · 1 shared drug class
  2. EMS · 1 shared drug class
  3. Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 1 shared drug class
  4. Liaoning University of Traditional Chinese Medicine · 1 shared drug class
  5. Reckitt Benckiser LLC · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Reckitt Benckiser Inc.:

Cite this brief

Drug Landscape (2026). Reckitt Benckiser Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/reckitt-benckiser-inc. Accessed 2026-05-15.

Related